Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ

@article{Adlard2008RapidRO,
  title={Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial A$\beta$},
  author={Paul A. Adlard and Robert A. Cherny and David Isaac Finkelstein and Elisabeth Gautier and Elysia L. Robb and Mikhalina Cort{\'e}s and Irene Volitakis and Xiang Liu and Jeffrey P. Smith and Keyla A. Perez and Katrina M. Laughton and Qiao-Xin Li and Susan A. Charman and Joseph A. Nicolazzo and Simon J Wilkins and Karolina Deleva and Toni Lynch and Gaik Beng Kok and Craig W. Ritchie and Rudolph E. Tanzi and Roberto Cappai and Colin L. Masters and Kevin J Barnham and Ashley I. Bush},
  journal={Neuron},
  year={2008},
  volume={59},
  pages={43-55}
}
As a disease-modifying approach for Alzheimer's disease (AD), clioquinol (CQ) targets beta-amyloid (Abeta) reactions with synaptic Zn and Cu yet promotes metal uptake. Here we characterize the second-generation 8-hydroxy quinoline analog PBT2, which also targets metal-induced aggregation of Abeta, but is more effective as a Zn/Cu ionophore and has greater blood-brain barrier permeability. Given orally to two types of amyloid-bearing transgenic mouse models of AD, PBT2 outperformed CQ by… Expand
Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.
Clioquinol (CQ) is a "metal protein attenuating compound" that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved inExpand
Copper Chelator Induced Efficient Episodic Memory Recovery in a Non-Transgenic Alzheimer’s Mouse Model
TLDR
The capacity of a new copper-specific chelating agent, a bis-8-aminoquinoline PA1637, to fully reverse the deficit of episodic memory after three weeks of treatment by oral route on non-transgenic amyloid-impaired mice is reported. Expand
WBQ5187, a Multitarget, Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-amyloid, Gliosis, cAMP Levels and Neurodegeneration.
TLDR
The results demonstrated that this compound markedly improves cognitive and spatial memory functions in AD mice and represents a promising pharmaceutical agent with potential for the treatment of AD. Expand
The aroylhydrazone INHHQ prevents memory impairment induced by Alzheimer’s-linked amyloid-β oligomers in mice
TLDR
Investigation of the protective action of an isoniazid-derived aroylhydrazone, INHHQ, on AβO-induced memory impairment in mice found it to prevent both short-term and long-term memory impairment caused by AβOs. Expand
Copper Modulation as a Therapy for Alzheimer's Disease?
TLDR
Novel animal data support an interaction between copper/cholesterol and both Aβ and APP and further highlight the potential role of metal ion dyshomeostasis in AD. Expand
Novel 8-hydroxyquinoline derivatives targeting β-amyloid aggregation, metal chelation and oxidative stress against Alzheimer's disease.
TLDR
The cell assays showed that 5b had excellent protective effects against oxidative toxin H2O2 and presented low neurotoxicity in PC12 cells, providing a rationale for the potential application of compound 5b as a lead compound in AD therapy. Expand
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
TLDR
Receiver-operator characteristic analyses and ranking the responses to treatment after 12 weeks revealed that the proportions of patients showing improvement on NTB Composite or Executive Factor z-scores were significantly greater in the PBT2 250 mg group than in the placebo group, which further encourage larger-scale testing of P BT2 for AD. Expand
Anti-copper therapies in Alzheimer's disease: new concepts.
TLDR
'old' and 'new' attitudes towards the use of anti-copper complexing agents or biological molecules which induce or maintain a state of copper malabsorption, such as zinc compounds are reviewed, paying special attention to how such a rethinking of 'old' clinical trials might trace new routes in planning 'modern' ones. Expand
Drug development based on the metals hypothesis of Alzheimer's disease.
  • A. Bush
  • Chemistry, Medicine
  • Journal of Alzheimer's disease : JAD
  • 2008
The recent report of positive results from a Phase IIa clinical trial of PBT2, a novel drug that targets amyloid-beta-metal interactions, underscores the value of abnormal transition metal metabolismExpand
Stabilization of Nontoxic Aβ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease
TLDR
It is proposed that 8-HQs possess an additional mechanism of action that neutralizes neurotoxic A β oligomer formation through stabilization of small (dimeric) nontoxic Aβ conformers. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
TLDR
A 49% decrease in brain Abeta deposition is reported in a blinded study of APP2576 transgenic mice treated orally for 9 weeks with clioquinol, an antibiotic and bioavailable Cu/Zn chelator, support targeting the interactions of Cu and Zn with Abeta as a novel therapy for the prevention and treatment of AD. Expand
Radioiodinated clioquinol as a biomarker for β‐amyloid: Zn2+ complexes in Alzheimer's disease
TLDR
The data support metallated Aβ species as the neuropharmacological target of CQ and indicate that this drug class may have potential as in vivo imaging agents for Alzheimer neuropathology. Expand
Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity*
TLDR
These findings identify an alternative mechanism of action for CQ in the reduction of Aβ deposition in the brains of CQ-treated animals and potentially in Alzheimer disease patients. Expand
The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice
TLDR
Results further support the hypothesis that endogenous metals are involved in the deposition of aggregated Abeta in brains of AD patients, and that metal chelators may be useful therapeutic agents in the treatment of AD. Expand
In vivo reduction of amyloid-β by a mutant copper transporter
TLDR
The data suggest that the beneficial effect of the txJ mutation on CNS Aβ burden may proceed by a previously undescribed mechanism, likely involving increased clearance of peripheral pools of Aβ peptide. Expand
In vivo reduction of amyloid-beta by a mutant copper transporter.
TLDR
The data suggest that the beneficial effect of the txJ mutation on CNS Abeta burden may proceed by a previously undescribed mechanism, likely involving increased clearance of peripheral pools of Abeta peptide. Expand
Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease
TLDR
It is shown that memory loss can be fully reversed in Tg2576 mice using intraperitoneally administered BAM-10, a monoclonal antibody recognizing the N terminus of Aβ, which postulates acts by neutralizing Aβ assemblies in the brain that impair cognitive function. Expand
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
TLDR
This pilot phase 2 study supports further investigation of this novel treatment strategy using a metal-protein-attenuating compound, and the effect of treatment was significant in the more severely affected group. Expand
Alzheimer disease β-amyloid activity mimics cholesterol oxidase
TLDR
It is shown that Abeta:Cu2+ complexes oxidize cholesterol selectively at the C-3 hydroxyl group, catalytically producing 4-cholesten-3-one and therefore mimicking the activity of cholesterol oxidase, which is implicated in cardiovascular disease. Expand
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
TLDR
Reducing endogenous tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein, without altering their high Aβ levels, and protected both transgenic and nontransgenic mice against excitotoxicity. Expand
...
1
2
3
4
5
...